PHARNEXT

📍 Paris, France🗓 Founded 2007👥 36 employees💰 Last funded Jun 2017
Biotechnology Research🌐 pharnext.com
Website LinkedIn
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy™ R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com. Pharnext is listed on the Euronext Growth Stock Exchange in Paris.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2007
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in PHARNEXT?
PHARNEXT has 1 investors on record on gritt.io.
When did PHARNEXT last raise funding?
The most recent investment in PHARNEXT recorded on gritt.io was in June 2017.
When was PHARNEXT founded?
PHARNEXT was founded in 2007.
What industry is PHARNEXT in?
PHARNEXT operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PHARNEXT based?
PHARNEXT is headquartered in Paris, France.